Shanghai - Delayed Quote CNY

Innovita Biological Technology Co., Ltd. (688253.SS)

33.40
-0.41
(-1.21%)
At close: 3:00:04 PM GMT+8
Loading Chart for 688253.SS
  • Previous Close 33.81
  • Open 33.61
  • Bid 33.38 x --
  • Ask 33.40 x --
  • Day's Range 33.34 - 34.27
  • 52 Week Range 27.56 - 52.69
  • Volume 1,997,177
  • Avg. Volume 3,214,243
  • Market Cap (intraday) 4.558B
  • Beta (5Y Monthly) 1.14
  • PE Ratio (TTM) 23.19
  • EPS (TTM) 1.44
  • Earnings Date --
  • Forward Dividend & Yield 0.40 (1.18%)
  • Ex-Dividend Date Jun 6, 2024
  • 1y Target Est --

Innovita Biological Technology Co., Ltd. engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products. The company offers pathogen detection and joint detection of multiple pathogen; emergency outpatient testing; coronavirus testing; respiratory infections solutions; pregnancy test; hepatitis virus testing ; and enterovirus testing . The company was founded in 2006 and is based in Beijing, China.

www.innovita.com.cn

547

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688253.SS

View More

Performance Overview: 688253.SS

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688253.SS
7.89%
SSE Composite Index (000001.SS)
0.10%

1-Year Return

688253.SS
15.76%
SSE Composite Index (000001.SS)
7.44%

3-Year Return

688253.SS
0.06%
SSE Composite Index (000001.SS)
6.40%

5-Year Return

688253.SS
0.06%
SSE Composite Index (000001.SS)
19.00%

Compare To: 688253.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688253.SS

View More

Valuation Measures

Annual
As of 5/22/2025
  • Market Cap

    4.61B

  • Enterprise Value

    2.64B

  • Trailing P/E

    23.48

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.43

  • Price/Book (mrq)

    2.24

  • Enterprise Value/Revenue

    4.83

  • Enterprise Value/EBITDA

    12.28

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    35.86%

  • Return on Assets (ttm)

    5.08%

  • Return on Equity (ttm)

    9.68%

  • Revenue (ttm)

    546.74M

  • Net Income Avi to Common (ttm)

    196.06M

  • Diluted EPS (ttm)

    1.44

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.98B

  • Total Debt/Equity (mrq)

    0.25%

  • Levered Free Cash Flow (ttm)

    205.93M

Research Analysis: 688253.SS

View More

Company Insights: 688253.SS

Research Reports: 688253.SS

View More

People Also Watch